title: Use of gemcitabine (GEM) in advanced myelodysplastic syndromes.
authors.forename: A D
authors.initials: AD
authors.lastname: Mario
authors.forename: L
authors.initials: L
authors.lastname: Pagano
authors.forename: L
authors.initials: L
authors.lastname: Mele
authors.forename: V
authors.initials: V
authors.lastname: De Stefano
authors.forename: G
authors.initials: G
authors.lastname: Leone
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine